ClinicalTrials.gg
CompletedNCT05197842Updated Aug 7, 2025

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

A Phase 1/2 interventional study of BDB-001 injection and Cyclophosphamide in ANCA-associated Vasculitis, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 22 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China — 42 open to participants now, 46 under way, 1 of them phase 3. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China.

Enrollment
6th of 52
93 · median 18
Started
2022
with 1 other
Phase 1/2
4 of 57
2 open now
Registered
7th of 57
by date
Lead sponsor
2 of 57
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Among the 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China, this one is the 6th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 1/2, and was the 7th registered.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

158 studies on the registry are indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; 76 are open to participants now.

Browse Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies →

Open to participants now

42 of the 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies recruiting now, 21 (38%) set no upper age limit and 28 (50%) stop at 75 or younger; 9 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China, or all of them as a file.
02

Study summary

The aim of the trial is to study the efficacy and safety of treatment with BDB-001 Injection substitution of glucocorticoid in patients with ANCA-associated vasculitis.

03

Conditions studied

  • ANCA-associated Vasculitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old≤Age≤75 years old, male or female;
  • Diagnosis of granulomatosis with polyangiitis(GPA) or microscopic polyangiitis(MPA);
  • Newly diagnosed or GPA or MPA that requires treatment with cyclophosphamide(CYC) and (GCs);
  • Positive test for anti-proteinase 3(PR3) or anti-myeloperoxidase (MPO);
  • Estimated ≥15 mL/minute/1.73 m\^2;
  • At least 1 major item, or at least 3 non-major items, or at least the 2 renal items on BVAS;

Exclusion criteria

Exclusion Criteria:

  • Active tuberculosis infection;
  • Severe disease as determined by rapidly progressive glomerulonephritis, alveolar hemorrhage requiring pulmonary ventilation support, rapid-onset mononeuritis multiplex or central nervous system involvement;
  • Any other known multi-system disease including eosinophilic granulomatosis with polyangiitis (Churg-Strauss), systemic lupus erythematosus, IgA vasculitis (Henoch-Schönlein), rheumatoid vasculitis,anti-glomerular basement membrane disease, or cryoglobulinemic vasculitis;
  • positive,or HBcAb positive and HBV-DNA positive;
  • Received CYC within 3 months before the first administration or Received rituximab(RTX) within 12 months before the first administration;
  • Received shock therapy within 4 weeks before the first administration;
  • Received an oral daily dose of a GC of > 10 mg prednisone-equivalent for more than 6 weeks continuously before the first administration;
  • Received a anti-tumor necrosis factor and other biological agents treatment within 12 weeks before the first administration;
  • Received Continuous dialysis treatment for 12 weeks or more before the first administration; Received Dialysis within 1 week before the first administration;
  • Received intravenous immunoglobulin (Ig) or plasma exchange within 4 weeks before the first administration;
  • Pregnant or lactating.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Group A

    BDB-001 injection low dose plus reduced dose glucocorticoids in combination with cyclophosphamide

    Drug: BDB-001 injection · Drug: Cyclophosphamide · Drug: Glucocorticoids

  • Experimental
    Group B

    BDB-001 injection high dose plus reduced dose glucocorticoids in combination with cyclophosphamide

    Drug: BDB-001 injection · Drug: Cyclophosphamide · Drug: Glucocorticoids

  • Active comparator
    Group C

    Standard dose glucocorticoids in combination with cyclophosphamide

    Drug: Cyclophosphamide · Drug: Glucocorticoids

  • Experimental
    Group D

    BDB-001 injection low dose in combination with cyclophosphamide

    Drug: BDB-001 injection · Drug: Cyclophosphamide

  • Experimental
    Group E

    BDB-001 injection high dose in combination with cyclophosphamide

    Drug: BDB-001 injection · Drug: Cyclophosphamide

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of patients achieving disease complete remission or partial remission assessed by Birmingham Vasculitis Activity Score (BVAS)

    Time frame: 12 weeks

Secondary outcomes

  1. The proportion of patients achieving disease complete remission assessed by Birmingham Vasculitis Activity Score (BVAS)

    Time frame: 12 weeks

  2. Change from baseline in the Birmingham Vasculitis Activity Score (BVAS)

    Time frame: 4 weeks、8 weeks、12 weeks

  3. Change from baseline in the Vasculitis Damage Index (VDI)

    Time frame: 12 weeks

  4. Change from baseline in Estimated glomerular filtration rate (eGFR)、Urinary albumin:creatinine ratio (UACR)、Urine erythrocyte

    Time frame: 4 weeks、8 weeks、12 weeks

  5. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    Safety and tolerability indexes of BDB-001 injection for multiple administration of ANCA-associated vasculitis(AAV) patients

    Time frame: 0-24weeks

  6. Number of Participants developing anti-BDB-001 antibodies.

    Safety and tolerability indexes of BDB-001 injection for multiple administration of ANCA-associated vasculitis(AAV) patients

    Time frame: 0-24weeks

  7. Area under the plasma concentration versus time curve (AUC) of BDB-001.

    Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.

    Time frame: 0-12 weeks

  8. Peak Plasma Concentration (Cmax) of BDB-001 and time to reach Cmax.

    Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.

    Time frame: 0-12 weeks

  9. Minimal Plasma Concentration (Cmin) of BDB-001.

    Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.

    Time frame: 0-12 weeks

  10. Terminal phase half-life.

    Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.

    Time frame: 0-12 weeks

  11. Change from baseline in C5a (mg/dL) concentration.

    Time frame: 0-12 weeks

07

Study locations

22 sites
  • The Second hospital Of Anhui Medical University
    Hefei, Anhui 230601, China
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100005, China
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Peking University International Hospital
    Beijing, Beijing Municipality 102206, China
  • Guangxi Academy of Medical Sciences,The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi Zhuang Autonomous Region (gzar) 530016, China
  • The Second hospital of Hebei Medical University
    Shijiazhuang, Hebei 050004, China
  • The Third hospital of Hebei Medical University
    Shijiazhuang, Hebei 050051, China
  • The First Affiliated Hospital of Henan University of science and Technology
    Luoyang, Henan 471003, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Tongji Hospital,Tongji Medical college of Hust
    Wuhan, Hubei 100005, China
  • Xiangya Hospital Central South University (Nephrology Department)
    Changsha, Hunan 410008, China
  • Xiangya Hospital Central South University(Rheumatism Immunity Branch)
    Changsha, Hunan 410008, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410205, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Shengjing Hospital of China Medical University
    Shengyang, Liaoning 110004, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia Hui Autonomous Region(NHAR) 750003, China
  • Zhongshan hospital,Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • Xijing Hospital
    Xi’an, Shanxi 710032, China
  • The First Affiliated Hospital of Xi'an Jiao Tong University
    Xi’an, Shanxi 710061, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • The First Affiliated Hospital, College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Mar 2025, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2021
First posted
Jan 20, 2022
StartActual
Feb 22, 2022
Primary completionActual
Mar 19, 2025
CompletionActual
Mar 19, 2025
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05197842
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
Feb 22, 2022
Primary completion
Mar 19, 2025
Completion
Mar 19, 2025
Last update
Aug 7, 2025

Study contacts

Minghui Zhao, Postdoc
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BDB001 · Corticosteroids

Start the discussion